|
Name |
Aloesone
|
Molecular Formula | C13H12O4 | |
IUPAC Name* |
7-hydroxy-5-methyl-2-(2-oxopropyl)chromen-4-one
|
|
SMILES |
CC1=CC(=CC2=C1C(=O)C=C(O2)CC(=O)C)O
|
|
InChI |
InChI=1S/C13H12O4/c1-7-3-9(15)5-12-13(7)11(16)6-10(17-12)4-8(2)14/h3,5-6,15H,4H2,1-2H3
|
|
InChIKey |
JHELBXAAAYUKCT-UHFFFAOYSA-N
|
|
Synonyms |
Aloesone; 40738-40-7; 5O7KO4M2YY; 2-Acetonyl-7-hydroxy-5-methyl-chromen-4-one; 2-actonyl-7-hydroxy-5-methylchromone; 5-methyl-7-hydroxy-2-(2'oxopropyl)chromone; 7-hydroxy-5-methyl-2-(2-oxopropyl)-4H-chromen-4-one; UNII-5O7KO4M2YY; CHEBI:59878; DTXSID20193721; 2-acetonyl-7-hydroxy-5-methylchromone; F78279; Q27126933; 2-(2-Oxopropyl)-7-hydroxy-5-methyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 7-hydroxy-5-methyl-2-(2-oxopropyl)-
|
|
CAS | 40738-40-7 | |
PubChem CID | 5317700 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 232.23 | ALogp: | 1.2 |
HBD: | 1 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 63.6 | Aromatic Rings: | 2 |
Heavy Atoms: | 17 | QED Weighted: | 0.864 |
Caco-2 Permeability: | -4.725 | MDCK Permeability: | 0.00001560 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.996 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.312 |
30% Bioavailability (F30%): | 0.071 |
Blood-Brain-Barrier Penetration (BBB): | 0.028 | Plasma Protein Binding (PPB): | 79.62% |
Volume Distribution (VD): | 0.902 | Fu: | 21.80% |
CYP1A2-inhibitor: | 0.959 | CYP1A2-substrate: | 0.906 |
CYP2C19-inhibitor: | 0.567 | CYP2C19-substrate: | 0.323 |
CYP2C9-inhibitor: | 0.38 | CYP2C9-substrate: | 0.931 |
CYP2D6-inhibitor: | 0.17 | CYP2D6-substrate: | 0.831 |
CYP3A4-inhibitor: | 0.147 | CYP3A4-substrate: | 0.368 |
Clearance (CL): | 6.83 | Half-life (T1/2): | 0.808 |
hERG Blockers: | 0.027 | Human Hepatotoxicity (H-HT): | 0.24 |
Drug-inuced Liver Injury (DILI): | 0.459 | AMES Toxicity: | 0.21 |
Rat Oral Acute Toxicity: | 0.077 | Maximum Recommended Daily Dose: | 0.636 |
Skin Sensitization: | 0.623 | Carcinogencity: | 0.035 |
Eye Corrosion: | 0.029 | Eye Irritation: | 0.685 |
Respiratory Toxicity: | 0.144 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003990 | 0.695 | D04AIT | 0.333 | ||||
ENC005306 | 0.673 | D0K8KX | 0.293 | ||||
ENC001620 | 0.673 | D06GCK | 0.278 | ||||
ENC006070 | 0.673 | D0FA2O | 0.274 | ||||
ENC001617 | 0.647 | D0O6KE | 0.272 | ||||
ENC005932 | 0.643 | D0G5UB | 0.262 | ||||
ENC006121 | 0.639 | D0E3OF | 0.261 | ||||
ENC005305 | 0.639 | D0G4KG | 0.253 | ||||
ENC006074 | 0.579 | D06FVX | 0.253 | ||||
ENC001763 | 0.525 | D0H2ZW | 0.244 |